A simple blood draw to evaluate cfDNA might one day be used for early-stage lung cancer screening—if the mutational “noise” of normal aging can be addressed.
This approach may lead to better understanding of risk-mitigation strategies, and perhaps better outcomes in patients with secondary AML.
A once-weekly regimen of carfilzomib plus dexamethasone improved response and delayed progression better than a twice-weekly regimen in R/R MM.
Despite paying nearly double per month for first-line treatment in the US, patients with mCRC have survival outcomes similar to their Canadian counterparts.
Genetic sequencing of tumors to identify targeted therapy options appears to delay tumor progression and prolong patient survival.
The PI3K inhibitor taselisib offered less dramatic clinical benefits than anticipated, and with significant toxicities.
The presence of MSI-high was predictive of Lynch syndrome, which was found to be associated with a much wider spectrum of cancers than previously thought.
Combining the ALK inhibitor with this immunotherapeutic agent had an acceptable safety profile and yielded an ORR of 85.7%, South Korean investigators reported.
In the Abi Race study, response to abiraterone was greater and longer lasting in black men with prostate cancer, compared with white men.
Ribociclib plus endocrine therapy resulted in improved PFS in premenopausal women with HR+, HER2− advanced breast cancer.